Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Cited by CrossRef (34)

  1. Norihisa Ishimura, Mami Mori, Hironobu Mikami, Shino Shimura, Goichi Uno, Masahito Aimi, Naoki Oshima, Shunji Ishihara, Yoshikazu Kinoshita. Effects of acotiamide on esophageal motor function and gastroesophageal reflux in healthy volunteers. BMC Gastroenterol 2015;15
    https://doi.org/10.1186/s12876-015-0346-7
  2. Hyun A. Lee, Kyeong-Ryoon Lee, Seong Bok Jang, Soo Yong Chung, Kyung-Sang Yu, Howard Lee. A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K+-competitive acid blocker. European Journal of Pharmaceutical Sciences 2019;130:1
    https://doi.org/10.1016/j.ejps.2019.01.009
  3. C. Prakash Gyawali, Ronnie Fass. Management of Gastroesophageal Reflux Disease. Gastroenterology 2018;154:302
    https://doi.org/10.1053/j.gastro.2017.07.049
  4. Ronnie Fass, Frederick Cahn, Dennis J. Scotti, David A. Gregory. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc 2017;31:4865
    https://doi.org/10.1007/s00464-017-5431-2
  5. Kiyoshi Ashida, Katsuhiko Iwakiri, Naoki Hiramatsu, Yuuichi Sakurai, Tetsuharu Hori, Kentarou Kudou, Akira Nishimura, Eiji Umegaki. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. WJG 2018;24:1550
    https://doi.org/10.3748/wjg.v24.i14.1550
  6. K. Ashida, Y. Sakurai, T. Hori, K. Kudou, A. Nishimura, N. Hiramatsu, E. Umegaki, K. Iwakiri. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016;43:240
    https://doi.org/10.1111/apt.13461
  7. Jun Matsukawa, Akifumi Kogame, Yoshihiko Tagawa, Nobuhiro Inatomi. Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa. Dig Dis Sci 2016;61:1888
    https://doi.org/10.1007/s10620-016-4100-y
  8. Jung Wan Choe, Moon Kyung Joo, Hyo Jung Kim, Beom Jae Lee, Ji Hoon Kim, Jong Eun Yeon, Jong-Jae Park, Jae Seon Kim, Kwan Soo Byun, Young-Tae Bak. Foods Inducing Typical Gastroesophageal Reflux Disease Symptoms in Korea. J Neurogastroenterol Motil 2017;23:363
    https://doi.org/10.5056/jnm16122
  9. Jun Gi Hwang, Hyounggyoon Yoo, Ji Won Lee, Geun Seog Song, SeungHwan Lee, Min-Gul Kim. Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects. Transl Clin Pharmacol 2019;27:80
    https://doi.org/10.12793/tcp.2019.27.2.80
  10. Zilla H Hussain, Emily E Henderson, Carla Maradey-Romerao, Nina George, Ronnie Fass, Brian E Lacy. The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum. Clinical and Translational Gastroenterology 2015;6:e106
    https://doi.org/10.1038/ctg.2015.32
  11. Carolin Maria Haas, Martina Maywald, Andreas Goetzenich, Christian Stoppe, Lothar Rink. Proton-pump inhibitors elevate infection rate in cardiothoracic surgery patients by influencing PMN function in vitro and in vivo. J Leukoc Biol 2018;103:777
    https://doi.org/10.1002/JLB.5A0417-143R
  12. J.M. Remes-Troche, F.D. García García, G. Rojas-Loureiro, X. Rivera-Gutiérrez, J. Reyes-Huerta, M. Amieva-Balmori. Efecto sobre el pH intragástrico de 20 mg de levopantoprazol versus 40 mg de pantoprazol racémico durante los primeros 7 días de tratamiento en pacientes con enfermedad por reflujo gastroesofágico. Revista de Gastroenterología de México 2019
    https://doi.org/10.1016/j.rgmx.2019.02.006
  13. Carlo A. Fallone, Naoki Chiba, Sander Veldhuyzen van Zanten, Lori Fischbach, Javier P. Gisbert, Richard H. Hunt, Nicola L. Jones, Craig Render, Grigorios I. Leontiadis, Paul Moayyedi, John K. Marshall. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016;151:51
    https://doi.org/10.1053/j.gastro.2016.04.006
  14. Young Sun Kim, Nayoung Kim, Gwang Ha Kim. Sex and Gender Differences in Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2016;22:575
    https://doi.org/10.5056/jnm16138
  15. Cheng-yuan Li, Mei Su, Yun-yi Yan, Lin Zhou, Lu-yao Ao, Wei-rong Fang, Yun-man Li. KFP-H008 blocks gastric acid secretion through inhibiting H + -K + -ATPase. European Journal of Pharmacology 2017;810:112
    https://doi.org/10.1016/j.ejphar.2017.06.020
  16. M.-L. Rouzade-Dominguez, N. Pezous, O. J. David, R. Tutuian, S. Bruley des Varannes, J. Tack, P. Malfertheiner, H.-D. Allescher, M. Ufer, A. Rühl. The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease. Neurogastroenterol Motil 2017;29:e13058
    https://doi.org/10.1111/nmo.13058
  17. Prashanth Rawla, Tagore Sunkara, Andrew Ofosu, Vinaya Gaduputi. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?. WJGPT 2018;9:63
    https://doi.org/10.4292/wjgpt.v9.i7.63
  18. Parth J. Parekh, David A. Johnson. Medical treatment versus surgery for treatment of gastroesophageal reflux disease. Techniques in Gastrointestinal Endoscopy 2015;17:53
    https://doi.org/10.1016/j.tgie.2015.02.003
  19. Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Kentaro Kudou, Akira Nishimura, Naoki Hiramatsu, Eiji Umegaki, Kiyoshi Ashida. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol 2017;10:439
    https://doi.org/10.1177/1756283X17705329
  20. Antonio M.M. Filho, Lyz B. Silva, Eduardo S. Godoy, Angela M. Falcão, Luiz G. de Quadros, Idiberto J. Zotarelli Filho, Josemberg M. Campos, Lucio V. Rabelo Filho. Omentopexy in Sleeve Gastrectomy Reduces Early Gastroesophageal Reflux Symptoms. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 2019;29:155
    https://doi.org/10.1097/SLE.0000000000000597
  21. Tatsuhiro Masaoka, Hisako Kameyama, Tsuyoshi Yamane, Yuta Yamamoto, Hiroya Takeuchi, Hidekazu Suzuki, Yuko Kitagawa, Takanori Kanai. Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test. J Neurogastroenterol Motil 2018;24:577
    https://doi.org/10.5056/jnm18036
  22. Hyunsoo Chung. Endoscopic Accessories Used for More Advanced Endoluminal Therapeutic Procedures. Clin Endosc 2017;50:234
    https://doi.org/10.5946/ce.2017.079
  23. Thiago Ferreira de SOUZA, Eduardo GRECCO, Luiz Gustavo de QUADROS, Yael Duarte de ALBUQUERQUE, Fernanda Oliveira AZÔR, Manoel GALVÃO NETO. SHORT-TERM RESULTS OF MINIMALLY INVASIVE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE BY RADIOFREQUENCY (STRETTA): FIRST BRAZILIAN SERIES OF CASES. Arq. Gastroenterol. 2018;55:52
    https://doi.org/10.1590/s0004-2803.201800000-51
  24. J.M. Remes-Troche, F.D. García García, G. Rojas-Loureiro, X. Rivera-Gutiérrez, J. Reyes-Huerta, M. Amieva-Balmori. Intragastric pH effect of 20 mg of levo-pantoprazole versus 40 mg of racemic pantoprazole the first seven days of treatment in patients with gastroesophageal reflux disease. Revista de Gastroenterología de México (English Edition) 2019
    https://doi.org/10.1016/j.rgmxen.2019.02.016
  25. Hironobu Mikami, Norihisa Ishimura, Mayumi Okada, Daisuke Izumi, Eiko Okimoto, Shunji Ishihara, Yoshikazu Kinoshita. Acotiamide Has No Effects on Esophageal Motor Activity or Esophagogastric Junction Compliance. J Neurogastroenterol Motil 2018;24:241
    https://doi.org/10.5056/jnm16111
  26. F. Khan, C. Maradey-Romero, S. Ganocy, R. Frazier, R. Fass. Utilisation of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013. Aliment Pharmacol Ther 2016;43:1124
    https://doi.org/10.1111/apt.13611
  27. Hyun Kang, Beom Jin Kim, Geunjoo Choi, Jae Gyu Kim. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease. Medicine 2018;97:e12574
    https://doi.org/10.1097/MD.0000000000012574
  28. Eunwoo Kim, Anhye Kim, Sojeong Yi, Yu Kyong Kim, Seong Bok Jang, Hae Mi Byun, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee. Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects. Eur J Clin Pharmacol 2018;74:1261
    https://doi.org/10.1007/s00228-018-2502-9
  29. C. R. Subramanian, G. Triadafilopoulos. Refractory gastroesophageal reflux disease. Gastroenterology Report 2015;3:41
    https://doi.org/10.1093/gastro/gou061
  30. Yi Wang, Guanwu Li, Xiaosu Wang, Shengliang Zhu. Effects of Shugan Hewei Granule on Depressive Behavior and Protein Expression Related to Visceral Sensitivity in a Rat Model of Nonerosive Reflux Disease. Evidence-Based Complementary and Alternative Medicine 2019;2019:1
    https://doi.org/10.1155/2019/1505693
  31. S.M. Freys, J. Heimbucher. Reflux und Hiatushernie im Spannungsfeld zwischen konservativer und operativer Therapie. Chirurg 2014;85:1046
    https://doi.org/10.1007/s00104-014-2804-0
  32. Jeffrey K. Aronson. Inhibiting the proton pump: mechanisms, benefits, harms, and questions. BMC Med 2016;14
    https://doi.org/10.1186/s12916-016-0724-1
  33. Carla Maradey-Romero, Ronnie Fass. New Therapies for Non-cardiac Chest Pain. Curr Gastroenterol Rep 2014;16
    https://doi.org/10.1007/s11894-014-0390-4
  34. Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai, Kazuyoshi Otake. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacology & Therapeutics 2016;168:12
    https://doi.org/10.1016/j.pharmthera.2016.08.001